Current Size: 100%

Ludwig Boltzmann Institute Cancer Research

The Ludwig Boltzmann Institute for Cancer Research (CR) was officially closed on December 31st, 2018. The projects and results of the LBI CR are still available here (last update: December 2018)

LBI-CR integrated into partner universities

After 14 years of successful research the Ludwig Boltzmann Institute for Cancer Research will come to it's scheduled end. Over more than a decade the institute developed an ambitious and internationally visible research portfolio developing and analysing genetically modified mouse models of disease under the guidance of a scientific advisory board and with substantial support from five partners.

LBG Health Sciences Meeting great success

The LBG Meeting for Health Sciences provides an important meeting point for the LBG Life Sciences community and provides young scientists an excellent opportunity to present their work. This conference focuses on the translation of research results from theory into practice. Therefore, abstracts on preclinical, clinical or implementation research were welcome in four thematic sessions:

European consortia are stepping up the development of state-of-the-art treatment for aggressive blood cancer with € 3 million in funding

New cancer therapies are now being developed specifically against oncogenic cell signals. But for rare diseases, these new drugs are often not approved. Two EU-consortia with Austrian participation have now received funding from the ERA-NET TRANSCAN-2 to develop modern treatments for rare but very aggressive peripheral T-cell lymphomas and leukemias.

Survival signalling mediated by Tyk2 is the Achilles’ heel of Anaplastic Large Cell Lymphomas

Anaplastic Large Cell Lymphomas (ALCL) are rare tumors of white blood cells, which fall into at least four categories. New research by the international ERIA consortium led by scientists in Vienna have now identified that all types of ALCL rely on the same signaling pathway for survival. TYK2 prevents apoptotic cell death by increasing the expression of the BCL2 family member Mcl1. Therefore TYK2 represents an attractive drug target due to its unique enzymatic domain, and TYK2-specific inhibitors show promise as novel targeted inhibitors for ALCL.

Afatinib might be rational treatment for many lung cancer patients

Lung cancer remains a serious health threat with less than one in five patients still alive 5 years after diagnosis. This is mainly due to the lack of modern treatment options for the majority of patients, which still receive classical chemotherapy. However, Emilio Casanova and Herwig Moll from the Ludwig Boltzmann Institute of Cancer Research (LBI-CR) and Medical University of Vienna (MUV) now describe in the journal Science Translational Medicine that the established drug Afatinib may prove an unexpected therapeutic option for many patients.

News

The Ludwig Boltzmann Institute for Cancer Research (CR) was officially closed on December 31st, 2018. The projects and results of the LBI CR are still available here (last update: December 2018)

LBI-CR integrated into partner universities

Award for Johannes Schmöllerl at LBG Health Science Meeting

LBG Health Sciences Meeting great success

European consortia are stepping up the development of state-of-the-art treatment for aggressive blood cancer with € 3 million in funding

Downloads

Current Report

Curriculum Vitae of team leaders

Annual Report Archives

Events

July

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

MeetScience TV

Meet Science TV - die neue Plattform für Wissenschaftspräsentation.
Sehen Sie hier Kurzfilme von allen Ludwig Boltzmann Institute und Cluster.

Search form

The Ludwig Boltzmann Institute for Cancer Research (CR) was officially closed on December 31st, 2018. The projects and results of the LBI CR are still available here (last update: December 2018)

LBI-CR integrated into partner universities

The Ludwig Boltzmann Institute for Cancer Research (CR) was officially closed on December 31st, 2018. The projects and results of the LBI CR are still available here (last update: December 2018)

LBG Health Sciences Meeting great success

The Ludwig Boltzmann Institute for Cancer Research (CR) was officially closed on December 31st, 2018. The projects and results of the LBI CR are still available here (last update: December 2018)

European consortia are stepping up the development of state-of-the-art treatment for aggressive blood cancer with € 3 million in funding

The Ludwig Boltzmann Institute for Cancer Research (CR) was officially closed on December 31st, 2018. The projects and results of the LBI CR are still available here (last update: December 2018)

Survival signalling mediated by Tyk2 is the Achilles’ heel of Anaplastic Large Cell Lymphomas

The Ludwig Boltzmann Institute for Cancer Research (CR) was officially closed on December 31st, 2018. The projects and results of the LBI CR are still available here (last update: December 2018)

Afatinib might be rational treatment for many lung cancer patients

News

Downloads

Events

July

MeetScience TV